Diagnosing reduced UGT activity involves a combination of clinical evaluation and laboratory testing. Genetic testing can identify specific polymorphisms that result in reduced enzyme activity. Additionally, liver function tests and specific assays measuring the metabolism of UGT substrates can provide insights into UGT activity. Healthcare professionals may also observe clinical symptoms such as prolonged drug half-lives or unexplained toxicities.
